

ASX Announcement
20 December 2022

Regeneus receives \$1.1 million R&D Tax Incentive Refund

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, is delighted to advise that it has received a refund of \$1,050,303 from the Australian Tax Office under the Federal Government's Research & Development (R&D) Tax Incentive Scheme. The R&D Tax rebate relates to activities conducted by the Company in the 2022 financial year.

The funds will be used to fund Regeneus' operations and bring its stem cell technology platform Progenza™ to market through its partnership with Kyocera Corporation in Japan. The Company will also progress the development of Sygenus for pain management and medical dermatology conditions in collaboration with the Australian Department of Defence.

-ENDS-

About Regeneus

Regeneus Ltd (ASX: RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on knee osteoarthritis, neuropathic pain, and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Contacts:

Karolis Rosickas, Chief Executive Officer, +61 404 626 029, karolis.rosickas@regeneus.com
Helen Leung, Corporate Secretary, 1300 995 098, helen.leung@regeneus.com